OPPORTUNITIES OF EARLY TREATMENT OF ACUTE RESPIRATORY VIRAL INFECTION IN CHILDREN
Purpose: to evaluate effectiveness of Oscillococcinum in the treatment of acute respiratory viral infections (ARVI) in children of different age groups.We observed 140 children from 1 to 14 years with mild to moderate-severe acute respiratory viral infection. 80 children (Group 1) were treated with...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
Ltd. “The National Academy of Pediatric Science and Innovation”
2018-11-01
|
| Series: | Rossijskij Vestnik Perinatologii i Pediatrii |
| Subjects: | |
| Online Access: | https://www.ped-perinatology.ru/jour/article/view/732 |
| _version_ | 1797875257591201792 |
|---|---|
| author | N. A. Gеppe N. A. Krylova T. I. Eliseeva E. N. Tyurina E. A. Yablokova |
| author_facet | N. A. Gеppe N. A. Krylova T. I. Eliseeva E. N. Tyurina E. A. Yablokova |
| author_sort | N. A. Gеppe |
| collection | DOAJ |
| description | Purpose: to evaluate effectiveness of Oscillococcinum in the treatment of acute respiratory viral infections (ARVI) in children of different age groups.We observed 140 children from 1 to 14 years with mild to moderate-severe acute respiratory viral infection. 80 children (Group 1) were treated with Oscillococcinum, 60 children (Group 2) were treated symptomatically. Group 1 was divided into Subgroup 1А (40 children of 1–5 years old) and Subgroup 1B (40 children >5–14 years old). Group 2 was divided into Subgroup 2А (30 children of 1–5 years old) and Subgroup 2B (30 children >5–14 years old). The follow-up period was 7–10 days. Clinical efficacy was assessed by the severity of ARVI symptoms in scores from 0 to 2. All adverse events of the therapy were recorded. Also we evaluated disappearance of ARVI symptoms within 48 hours after the beginning of the therapy.Results: Oscillococcinum reduced the duration of ARVI in children of different age groups. During the first two days the symptoms of acute respiratory viral infection disappeared in 13 (16.3%) children of Group 1 receiving oscilococcinum and in 4 (6.7%) patients from Group 2 (OR = 2.7, 95 % CI 0.8–8.8, p <0.001).Conclusion: Oscillococcinum is an effective and safe drug to treat ARVI in children of different age groups. |
| first_indexed | 2024-04-10T01:43:40Z |
| format | Article |
| id | doaj.art-a9d5e57fb6fa47d091857625dd64827a |
| institution | Directory Open Access Journal |
| issn | 1027-4065 2500-2228 |
| language | Russian |
| last_indexed | 2024-04-10T01:43:40Z |
| publishDate | 2018-11-01 |
| publisher | Ltd. “The National Academy of Pediatric Science and Innovation” |
| record_format | Article |
| series | Rossijskij Vestnik Perinatologii i Pediatrii |
| spelling | doaj.art-a9d5e57fb6fa47d091857625dd64827a2023-03-13T09:12:45ZrusLtd. “The National Academy of Pediatric Science and Innovation”Rossijskij Vestnik Perinatologii i Pediatrii1027-40652500-22282018-11-01635103107638OPPORTUNITIES OF EARLY TREATMENT OF ACUTE RESPIRATORY VIRAL INFECTION IN CHILDRENN. A. Gеppe0N. A. Krylova1T. I. Eliseeva2E. N. Tyurina3E. A. Yablokova4ФГАОУ ВО «Первый Московский государственный медицинский университет имени И.М. Сеченова» Минздрава РФ.ФГАОУ ВО «Первый Московский государственный медицинский университет имени И.М. Сеченова» Минздрава РФ.ФГБОУ ВО “Приволжский исследовательский медицинский университет” Минздрава РФ.ФГАОУ ВО «Первый Московский государственный медицинский университет имени И.М. Сеченова» Минздрава РФ.ФГАОУ ВО «Первый Московский государственный медицинский университет имени И.М. Сеченова» Минздрава РФ.Purpose: to evaluate effectiveness of Oscillococcinum in the treatment of acute respiratory viral infections (ARVI) in children of different age groups.We observed 140 children from 1 to 14 years with mild to moderate-severe acute respiratory viral infection. 80 children (Group 1) were treated with Oscillococcinum, 60 children (Group 2) were treated symptomatically. Group 1 was divided into Subgroup 1А (40 children of 1–5 years old) and Subgroup 1B (40 children >5–14 years old). Group 2 was divided into Subgroup 2А (30 children of 1–5 years old) and Subgroup 2B (30 children >5–14 years old). The follow-up period was 7–10 days. Clinical efficacy was assessed by the severity of ARVI symptoms in scores from 0 to 2. All adverse events of the therapy were recorded. Also we evaluated disappearance of ARVI symptoms within 48 hours after the beginning of the therapy.Results: Oscillococcinum reduced the duration of ARVI in children of different age groups. During the first two days the symptoms of acute respiratory viral infection disappeared in 13 (16.3%) children of Group 1 receiving oscilococcinum and in 4 (6.7%) patients from Group 2 (OR = 2.7, 95 % CI 0.8–8.8, p <0.001).Conclusion: Oscillococcinum is an effective and safe drug to treat ARVI in children of different age groups.https://www.ped-perinatology.ru/jour/article/view/732детиострые респираторные вирусные инфекциигомеопатические средстваоциллококцинумлечение |
| spellingShingle | N. A. Gеppe N. A. Krylova T. I. Eliseeva E. N. Tyurina E. A. Yablokova OPPORTUNITIES OF EARLY TREATMENT OF ACUTE RESPIRATORY VIRAL INFECTION IN CHILDREN Rossijskij Vestnik Perinatologii i Pediatrii дети острые респираторные вирусные инфекции гомеопатические средства оциллококцинум лечение |
| title | OPPORTUNITIES OF EARLY TREATMENT OF ACUTE RESPIRATORY VIRAL INFECTION IN CHILDREN |
| title_full | OPPORTUNITIES OF EARLY TREATMENT OF ACUTE RESPIRATORY VIRAL INFECTION IN CHILDREN |
| title_fullStr | OPPORTUNITIES OF EARLY TREATMENT OF ACUTE RESPIRATORY VIRAL INFECTION IN CHILDREN |
| title_full_unstemmed | OPPORTUNITIES OF EARLY TREATMENT OF ACUTE RESPIRATORY VIRAL INFECTION IN CHILDREN |
| title_short | OPPORTUNITIES OF EARLY TREATMENT OF ACUTE RESPIRATORY VIRAL INFECTION IN CHILDREN |
| title_sort | opportunities of early treatment of acute respiratory viral infection in children |
| topic | дети острые респираторные вирусные инфекции гомеопатические средства оциллококцинум лечение |
| url | https://www.ped-perinatology.ru/jour/article/view/732 |
| work_keys_str_mv | AT nageppe opportunitiesofearlytreatmentofacuterespiratoryviralinfectioninchildren AT nakrylova opportunitiesofearlytreatmentofacuterespiratoryviralinfectioninchildren AT tieliseeva opportunitiesofearlytreatmentofacuterespiratoryviralinfectioninchildren AT entyurina opportunitiesofearlytreatmentofacuterespiratoryviralinfectioninchildren AT eayablokova opportunitiesofearlytreatmentofacuterespiratoryviralinfectioninchildren |